Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Agentic AI Personalized Dietary Management Study (AIDiet)

11 de septiembre de 2026 actualizado por: Su-Yeon Choi, Seoul National University Hospital

Effectiveness of an Agentic AI-Based Personalized Dietary Management Algorithm in Health Screening Participants: A Randomized Controlled Trial

This randomized controlled trial aims to evaluate the effectiveness of an Agentic AI-based personalized dietary management algorithm among adults undergoing health screening. Participants will be assigned to a control group, a static goal AI intervention group, or an adaptive goal AI intervention group and followed for 12 weeks.

Descripción general del estudio

Descripción detallada

This study is a randomized controlled trial designed to evaluate whether an Agentic AI-based personalized dietary management algorithm improves dietary behavior and metabolic health indicators among adults undergoing health screening. Eligible participants will be randomly assigned to one of three groups: standard dietary education and passive dietary recording, AI-generated personalized dietary goals maintained throughout the study period, or adaptive AI-based dietary tracking with dynamic goal adjustment and personalized feedback. Outcomes will be assessed at baseline and after 12 weeks, including dietary evaluation index scores and metabolic health-related clinical indicators.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

200

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Suyeon Choi, MD, PhD
  • Número de teléfono: 02-2112-5639
  • Correo electrónico: 65390@snuh.org

Ubicaciones de estudio

    • Seoul
      • Seoul, Seoul, Corea del Sur, 06236
        • Reclutamiento
        • Seoul National University Hospital Healthcare System Gangnam Center
        • Contacto:
          • Su-Yeon Choi, PhD
          • Número de teléfono: +82-10-2028-5782
          • Correo electrónico: 65390@snuh.org

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Adults aged 20 years or older
  • Individuals from the general population who underwent a health examination at the Seoul National University Hospital Healthcare System Gangnam Center
  • Individuals who are capable of independently using a smartphone and operating study-related applications or text messaging functions
  • Individuals without conditions that significantly interfere with standard dietary management, as specified in the exclusion criteria [Section 9.2 Exclusion Criteria]

Exclusion Criteria:

  • Individuals unable to use a smartphone or study-related digital program/application, including those without a smartphone or unable to operate text messaging or application-based functions.
  • End-stage renal disease or patients currently receiving dialysis
  • Active cancer or currently undergoing chemotherapy or radiotherapy
  • Severe heart failure, liver cirrhosis, or hepatic insufficiency accompanied by varices, bleeding, ascites, hepatic encephalopathy, or jaundice
  • Malabsorption disorders such as Crohn's disease or short bowel syndrome
  • Poorly controlled hyperthyroidism or hypothyroidism
  • Diagnosed eating disorders or severe psychiatric disorders
  • Pregnant or breastfeeding women, or women who may become pregnant during study participation.
  • Individuals with recent major weight-related interventions or extreme body weight changes within the past 3 months, including:Bariatric surgery such as gastrectomy or gastric bypass surgery Newly initiated anti-obesity pharmacotherapy (e.g., semaglutide/Wegovy, tirzepatide/Mounjaro)
  • Individuals considered by the investigator to have poor compliance potential or otherwise deemed unsuitable for participation in the clinical study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Control group
Participants receive standard dietary education and perform passive dietary recording during the 12-week study period.
Experimental: Static goal AI intervention group
Participants receive AI-generated personalized dietary goals that are maintained during the 12-week intervention period.
The AI algorithm generates individualized dietary goals based on baseline information. The generated goals are maintained without dynamic adjustment during the intervention period.
Experimental: Adaptive goal AI intervention group
Participants receive adaptive AI-based dietary tracking, dynamic goal adjustment, and personalized feedback during the 12-week intervention period.
The AI algorithm monitors dietary records and relevant participant information, adjusts dietary goals dynamically, and provides personalized feedback to support dietary behavior change.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Dietary Behavior Score
Periodo de tiempo: Baseline and 12 weeks
Dietary behavior will be assessed using a 12-item dietary behavior questionnaire derived from a 19-item dietary assessment questionnaire developed and routinely used at Seoul National University Hospital Gangnam Center. Each item is scored on a 3-point scale (1, 3, or 5 points). Total scores range from 12 to 60, with higher scores indicating healthier dietary behaviors. The change in total dietary behavior score from baseline to 12 weeks will be evaluated. unit:score
Baseline and 12 weeks
Outcome Measure: Change in Client Satisfaction Questionnaire Score (CSQ-8)
Periodo de tiempo: from baseline to 12 weeks.
Participant satisfaction with the system will be assessed using the Client Satisfaction Questionnaire-8 (CSQ-8). Total scores range from 8 to 32, with higher scores indicating greater satisfaction with the system.unit:score
from baseline to 12 weeks.
Change in System Usability Scale Score (SUS)
Periodo de tiempo: from baseline to 12 weeks
System usability will be assessed using the System Usability Scale (SUS). Total scores range from 0 to 100, with higher scores indicating better usability. unit:score
from baseline to 12 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Body Mass Index
Periodo de tiempo: Baseline and 12 weeks
Change in body mass index from baseline to 12 weeks. Unit: kg/m²
Baseline and 12 weeks
Change in Waist Circumference
Periodo de tiempo: from baseline to 12 weeks
Change in waist circumference from baseline to 12 weeks. Unit : cm
from baseline to 12 weeks
Change in Systolic Blood Pressure
Periodo de tiempo: from baseline to 12 weeks.
Change in systolic blood pressure from baseline to 12 weeks.Unit:mmHg
from baseline to 12 weeks.
Change in Diastolic Blood Pressure
Periodo de tiempo: from baseline to 12 week
Change in diastolic blood pressure from baseline to 12 weeks. Unit:mmHg
from baseline to 12 week
Change in Fasting Glucose
Periodo de tiempo: from baseline to 12 weeks.
Change in fasting glucose from baseline to 12 weeks. Unit:mg/dL
from baseline to 12 weeks.
Change in HbA1c
Periodo de tiempo: from baseline to 12 week
Change in HbA1c from baseline to 12 weeks.Unit:%
from baseline to 12 week
Change in total cholesterol
Periodo de tiempo: from baseline to 12 weeks
Changes in total cholesterol from baseline to 12 weeks. unit: mg/dL
from baseline to 12 weeks
Change in AST
Periodo de tiempo: from baseline to 12 weeks
Changes in AST from baseline to 12 weeks.unit: U/L
from baseline to 12 weeks
Change in Body fat mass
Periodo de tiempo: from baseline to 12 weeks
Changes in body fat mass from baseline to 12 weeks. unit : kg
from baseline to 12 weeks
Change in skeletal muscle mass
Periodo de tiempo: from baseline to 12 weeks
Changes in skeletal muscle mass from baseline to 12 weeks. unit:kg
from baseline to 12 weeks
Change in percent body fat
Periodo de tiempo: from baseline to 12 weeks.
Changes in percent body fat from baseline to 12 weeks. unit:%
from baseline to 12 weeks.
Change in body weight (kg)
Periodo de tiempo: from baseline to 12 weeks
Change in body weight from baseline to 12 weeks unit: kg
from baseline to 12 weeks
Changes in LDL cholesterol
Periodo de tiempo: from baseline to 12 weeks
Changes in LDL cholesterol from baseline to 12 weeks. unit: mg/dL
from baseline to 12 weeks
Changes in HDL cholesterol
Periodo de tiempo: from baseline to 12 weeks
Changes in HDL cholesterol from baseline to 12 weeks. unit: mg/dL
from baseline to 12 weeks
Changes in triglycerides
Periodo de tiempo: from baseline to 12 weeks.
Changes in triglycerides from baseline to 12 weeks.
from baseline to 12 weeks.
Changes in ALT
Periodo de tiempo: from baseline to 12 weeks
Changes in ALT from baseline to 12 weeks.unit: U/L
from baseline to 12 weeks
Changes in γ-GTP
Periodo de tiempo: from baseline to 12 weeks
Changes in γ-GTP from baseline to 12 weeks.unit: U/L
from baseline to 12 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

11 de junio de 2026

Finalización primaria (Estimado)

26 de febrero de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

31 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

4 de junio de 2026

Publicado por primera vez (Actual)

10 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

15 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de septiembre de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir